Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicorandil added to standard three-drug therapy for coronary slow flow syndrome
IRCT20221228056964N1Phase 3Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nicorandil in Slow Coronary Flow (SCF) (2 arms), sponsored by Qazvin University of Medical Sciences. Primary endpoint: Reduction of clinical symptoms. Started Jan 2023; status: completed.
02
Drugs
nicorandil
03
Conditions
Slow Coronary Flow (SCF)
Beyond the preview
Go deeper on IRCT20221228056964N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221228056964N1.